Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J; the ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27:v111–8.

Article  Google Scholar 

Aagaard T, Reekie J, Jorgensen M, Roen A, Daugaard G, Specht L, et al. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer. Cancer Med. 2020;9(9):3033–42.

Article  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Resources. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.

Article  PubMed  Google Scholar 

Li Y, Klippel Z, Shih X, Reiner M, Wang H, Page JH. Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies. Support Care Cancer. 2016;24:4377–83.

Article  PubMed  Google Scholar 

Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552–e61.

Article  PubMed  PubMed Central  Google Scholar 

Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D, et al. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Support Care Cancer. 2021;29(4):2179–86.

Article  PubMed  Google Scholar 

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325(3):164–70.

Article  CAS  PubMed  Google Scholar 

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12(11):2471–508.

Article  Google Scholar 

Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18(20):3558–85.

Article  CAS  PubMed  Google Scholar 

Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–84.

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN Guidelines for Hematopoietic Growth Factors. Version 2. 2023. Available from: www.nccn.org/guidelines/guidelines-detail?category=3&id=1493

Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.

Article  CAS  PubMed  Google Scholar 

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33(28):3199–212.

Article  CAS  PubMed  Google Scholar 

European Society for Medical Oncology. Supportive care strategies during the COVID-19 pandemic. Available from: www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/supportive-care-in-the-covid-19-era

Prabhakar M, Ershler WB, Longo DL. Bone marrow, thymus and blood: changes across the lifespan. Aging Health. 2009;5:385–93.

Article  Google Scholar 

Link H, Kerkmann M, Holtmann L, Ortner P. G‑CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer. 2019;27(4):1459–69.

Article  PubMed  Google Scholar 

Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995;332(14):901–6.

Article  CAS  PubMed  Google Scholar 

Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat. 2009;114(3):479–84.

Article  CAS  PubMed  Google Scholar 

Leonard RC, Mansi JL, Keerie C, Yellowlees A, Crawford S, Benstead K, et al. A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (’SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN. Ann Oncol. 2015;26(12):2437–41.

Article  CAS  PubMed  Google Scholar 

Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol. 2022;23(12):1571–82.

Article  PubMed  Google Scholar 

Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B‑cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277–83.

Article  CAS  PubMed  Google Scholar 

Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87(5):429–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–41.

Article  CAS  PubMed  Google Scholar 

Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3‑weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626–33.

Article  CAS  PubMed  Google Scholar 

Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense R‑CHOP-14 supported by pegfilgrastim in patients with diffuse large B‑cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91(4):496–502.

CAS  PubMed  Google Scholar 

Moore DC. Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia. P T. 2016;41(12:765–8.

Google Scholar 

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.

Article  PubMed  Google Scholar 

ClinicalTrials.gov. Phase II study of atezolizumab + FLOT vs. FLOT alone in patients with gastric cancer and GEJ (DANTE). Available from: https://clinicaltrials.gov/ct2/show/NCT03421288

Al-Batran SE, Lorenzen S, Thuss-Patience PC, Homann N, Schenk M, Lindig U, et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. J Clin Oncol. 2022;40:4003.

Article  Google Scholar 

Canton C, Boussari O, Boulin M, Le Malicot K, Taieb J, Dahan L, et al. Impact of G‑CSF prophylaxis on chemotherapy dose-intensity, link between dose-intensity and survival in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2022;27(7):e571–e9.

Article  PubMed  PubMed Central  Google Scholar 

Lyman GH, Yau L, Nakov R, Krendyukov A. Overall survival and risk of second malignancies with cancer chemotherapy and G‑CSF support. Ann Oncol. 2018;29(9):1903–10.

Article  CAS  PubMed  Google Scholar 

Truong J, Lee EK, Trudeau ME, Chan KK. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):608–18.

Article  CAS  PubMed  Google Scholar 

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Educ. 2020;35(1):178–86.

Article  PubMed  Google Scholar 

Zullo AR, Lou U, Cabral SE, Huynh J, Berard-Collins CM. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia. J Oncol Pharm Pract. 2019;25(6):1357–65.

Article  CAS  PubMed  Google Scholar 

Dittrich CK, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, et al. ESMO / ASCO recommendations for a global curriculum in medical oncology edition. Esmo Open. 2016;2016(1):e97.

Google Scholar 

Bernens JN, Hartman K, Curley B, Wen S, Rogers J, Abraham J, et al. Assessing the impact of a targeted electronic medical record intervention on the use of growth factor in cancer patients. J Community Support Oncol. 2015;13(3):113–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

European Medicines Agency. Ziextenzo. Summary of Product Characteristics. Published 2019. Available From: wwwe.ema.europa.eu/en/documents/product-information/ziextenzo-epar-product-information_en.pdf.

European Medicines Agency. Zarzio. Summary of Product Characteristics. Updated 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/zarzio-epar-product-information_en.pdf

McCullough J, Clay M, Herr G, Smith J, Stroncek D. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors. Transfusion. 1999;39(10):1136–40.

Article  CAS  PubMed